The market for retail pharmacy sales rose 15.8% during the second quarter, according to Newton, PA-based Scott-Levin. In its "Source Prescription Audit," the company reported that pharmaceutical companies generated a total of $20.7 billion during the quarter.
The market for retail pharmacy sales rose 15.8% during the second quarter, according to Newton, PA-based Scott-Levin. In its "Source Prescription Audit," the company reported that pharmaceutical companies generated a total of $20.7 billion during the quarter.
Driven by the success of Imitrex, Flonase, Epivir and Serevent, Glaxo Wellcome was responsible for the largest portion (6.7%) of retail pharmacy sales. Merck added the second largest share (6.5%) with Aocor, Fosamax, Cozaar and Hyzaar. Pfizer contributed the third largest sales (6.2%) with strong performances by Norvasc, Cardura, Zithromax and Zyrtec.
American Home Products and Bristol-Myers Squibb rounded out the top five in second-quarter sales with 6% and 5.7%, respectively.
Four of the top 10 corporations increased their U.S. retail pharmacy dollars by more than 20%: Eli Lilly and SmithKline Beecham raised their revenues by 21%; Bristol-Myers Squibb improved its stance by 24%; and Schering-Plough boosted its sales by 32%. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.